Pediatric Dermatology: Common Conditions in Children and Adolescents

Skin conditions are among the most frequent reasons children and adolescents visit a physician, accounting for a substantial portion of pediatric ambulatory care visits across the United States each year. This page covers the definition and scope of pediatric dermatology, the structural mechanics of how childhood skin differs from adult skin, the major condition categories and their causal drivers, classification boundaries, clinical tradeoffs, and corrective information on widely held misconceptions. The reference table and condition checklist at the end provide a structured overview for readers seeking to understand how these conditions are organized and evaluated.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix

Definition and Scope

Pediatric dermatology is the subspecialty of dermatology focused on the diagnosis and management of skin, hair, and nail disorders in patients from birth through late adolescence — generally defined as ages 0 through 18. Within that range, practitioners distinguish neonates (0–28 days), infants (1–12 months), toddlers (1–3 years), school-age children (4–12 years), and adolescents (13–18 years), because disease expression, treatment tolerability, and dosing constraints differ substantially across these subgroups.

The American Academy of Dermatology (AAD) recognizes pediatric dermatology as one of its formal subspecialty tracks, and board-certified pediatric dermatologists complete additional fellowship training beyond the standard 3-year dermatology residency. The breadth of the subspecialty spans congenital and genetic disorders (such as epidermolysis bullosa and ichthyosis), inflammatory conditions (atopic dermatitis, psoriasis), infectious conditions (impetigo, molluscum contagiosum, tinea capitis), and acne, which becomes the dominant concern in adolescence.

The skin conditions overview page provides broader context for how pediatric presentations relate to adult dermatology more generally, while dermatology subspecialties describes how pediatric dermatology fits within the credentialing landscape.

Core Mechanics or Structure

Childhood skin is structurally and functionally distinct from adult skin in ways that directly affect how conditions develop, present, and respond to treatment.

Barrier function: The stratum corneum — the outermost epidermal layer responsible for transepidermal water loss (TEWL) regulation — reaches adult-equivalent maturity at approximately 34 weeks of gestational age. Preterm neonates have an incompletely cornified barrier, making them highly susceptible to percutaneous absorption of topical agents and to fluid loss. Even full-term infants have a higher TEWL than adults because their skin surface area–to–body weight ratio is larger.

Immune response: The adaptive immune system is incompletely developed at birth. Th2-skewed immune responses in early infancy contribute to the high prevalence of atopic (IgE-mediated) inflammation during the first 2 years of life, consistent with the "atopic march" framework described by the National Institute of Allergy and Infectious Diseases (NIAID).

Sebaceous activity: Sebaceous glands are androgen-sensitive. They are relatively active in neonates due to maternal androgen exposure (explaining neonatal acne), then quiescent in early childhood, then progressively reactivated during adrenarche (typically ages 8–10) and full puberty, which drives the onset of adolescent acne.

Melanocyte density: Melanocyte count per unit area is approximately equal in children and adults, but melanosomes in lighter-skinned children are smaller and produce less melanin, which affects both the clinical appearance of lesions and sun-sensitivity risk.

Causal Relationships or Drivers

Pediatric skin conditions arise from interactions among genetic predisposition, immune maturation, environmental exposure, and microbial colonization.

Atopic dermatitis (eczema): Mutations in the FLG gene, which encodes filaggrin — a protein critical to the epidermal barrier — are present in approximately 30% of patients with moderate-to-severe atopic dermatitis, according to research cited in the National Eczema Association's published literature. Barrier disruption allows allergen and microbial penetration, driving IgE sensitization. Staphylococcus aureus colonizes the skin of more than 90% of atopic dermatitis patients (compared with roughly 20% of healthy controls), contributing to flare cycles through toxin-mediated immune activation.

Acne vulgaris: Sebum overproduction, follicular hyperkeratinization, Cutibacterium acnes (formerly Propionibacterium acnes) colonization, and inflammatory signaling are the 4 established pathogenic pillars. Androgen surges during puberty drive sebaceous hyperplasia; the sebum-rich follicular environment then supports bacterial overgrowth.

Tinea capitis: Caused by dermatophyte fungi, predominantly Trichophyton tonsurans in the United States (responsible for more than 90% of tinea capitis cases per CDC-cited epidemiological data), spread occurs via direct contact and fomites such as combs and hats. Incidence peaks between ages 3 and 9.

Molluscum contagiosum: A poxvirus transmitted by skin-to-skin contact and shared surfaces. The immune system of young children has not yet encountered the molluscum contagiosum virus (MCV), accounting for its higher prevalence in school-age cohorts.

Psoriasis: Up to one-third of psoriasis patients have onset before age 20, according to data from the National Psoriasis Foundation. Pediatric psoriasis is often triggered by Group A Streptococcal pharyngitis (guttate pattern), distinguishing it mechanistically from plaque-dominant adult onset.

Classification Boundaries

Pediatric skin conditions are classified along two principal axes: age at onset and pathogenic mechanism.

By age at onset:
- Neonatal conditions (0–4 weeks): erythema toxicum neonatorum, transient neonatal pustular melanosis, sebaceous hyperplasia, milia, neonatal acne
- Infantile conditions (1–12 months): infantile hemangiomas, infantile seborrheic dermatitis ("cradle cap"), atopic dermatitis onset
- Early childhood conditions (1–6 years): molluscum contagiosum, impetigo, tinea corporis
- School-age conditions (6–12 years): tinea capitis, warts (verruca vulgaris), pityriasis rosea
- Adolescent conditions (12–18 years): acne vulgaris, hidradenitis suppurativa onset, cystic acne

By pathogenic mechanism:
- Inflammatory/immune-mediated: atopic dermatitis, psoriasis, contact dermatitis, urticaria
- Infectious: impetigo (Staphylococcus aureus, Streptococcus pyogenes), tinea capitis, molluscum contagiosum, herpes simplex
- Structural/vascular: port wine stains (capillary vascular malformations), infantile hemangiomas, epidermolysis bullosa
- Endocrine-driven: neonatal acne, adolescent acne, acanthosis nigricans (associated with insulin resistance)

The distinction between vascular tumors (such as infantile hemangiomas, which proliferate then involute) and vascular malformations (such as port wine stains, which are present at birth and persist) is clinically critical because management differs entirely. The AAD clinical guidelines address this distinction in their nevus and vascular lesion frameworks.

The regulatory context for dermatology page outlines how FDA oversight of pediatric topical and systemic treatments interacts with these diagnostic categories — pediatric labeling requirements under the Pediatric Research Equity Act (PREA, 21 U.S.C. § 355c) directly affect which agents carry pediatric-specific dosing data.

Tradeoffs and Tensions

Topical corticosteroid use in children: Corticosteroids remain a mainstay of atopic dermatitis management, but their use in pediatric patients generates ongoing tension between efficacy and the risk of hypothalamic–pituitary–adrenal (HPA) axis suppression. Children have a higher skin surface area–to–body weight ratio, increasing systemic absorption per gram applied. The AAD's atopic dermatitis guidelines acknowledge this tension and stratify potency recommendations by patient age and body site.

Isotretinoin in adolescents: Isotretinoin (Accutane and generics) is highly effective for severe cystic acne but carries teratogenic risk and requires enrollment in the FDA's iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program. Prescribing to adolescent patients introduces psychosocial monitoring requirements, as the FDA label notes a possible association with mood disturbance, though causality remains debated in published literature.

Watchful waiting versus active treatment for molluscum: Because molluscum contagiosum is self-limiting in immunocompetent children — resolving within 6 to 18 months in most cases — the clinical debate centers on whether procedural interventions (cantharidin, curettage) impose unnecessary discomfort relative to their marginal acceleration of clearance.

Biologic agents in pediatric psoriasis: Biologics such as etanercept and secukinumab have FDA-approved pediatric indications for plaque psoriasis, but long-term immunosuppression data in pediatric populations remain more limited than in adults. The balance between disease burden and safety uncertainty is a recognized gap in the literature as catalogued by the Cochrane Skin Group.

Common Misconceptions

Misconception: Atopic dermatitis is caused by poor hygiene.
Correction: Atopic dermatitis is a genetically mediated barrier dysfunction with an immune component. FLG mutations and Th2-skewed immune responses are structural contributors unrelated to cleanliness. Overwashing with harsh soaps can actually worsen barrier disruption.

Misconception: Children "outgrow" eczema completely.
Correction: Approximately 40% to 60% of children with atopic dermatitis have persistent or recurrent disease into adulthood, according to data synthesized by NIAID. "Outgrowing" occurs in a subset, not the majority of moderate-to-severe cases.

Misconception: Sunscreen is unsafe for infants under 6 months.
Correction: The AAD recommends avoiding prolonged sun exposure and using protective clothing as the primary strategy for infants under 6 months. Sunscreen is not broadly contraindicated for this age group; rather, limited skin surface application is acceptable when shade and clothing are insufficient, per AAD guidance updated in its sun protection position statements.

Misconception: Acne in adolescents is always caused by poor diet.
Correction: The relationship between diet and acne is subject to ongoing research. High glycemic load diets and dairy consumption have been associated with acne severity in peer-reviewed studies (notably published in the Journal of the Academy of Nutrition and Dietetics and the American Journal of Clinical Nutrition), but diet is one contributor among 4 established pathogenic mechanisms, not the primary cause.

Misconception: Tinea capitis can be treated with topical antifungal creams alone.
Correction: Tinea capitis involves follicular and hair shaft infection that topical antifungals cannot adequately penetrate. Oral antifungal therapy (griseofulvin or terbinafine) is required, a point explicitly addressed in AAD clinical practice guidelines for tinea capitis.

Checklist or Steps (Non-Advisory)

The following structured sequence reflects how pediatric skin conditions are typically evaluated in a clinical dermatology encounter. This is a descriptive framework, not clinical advice.

Standard Evaluation Framework for Pediatric Skin Conditions:

1. Age and developmental stage documentation — Determine neonatal, infant, childhood, or adolescent category, as this shapes differential diagnosis directly.
2. Onset timeline — Establish whether the condition was present at birth (congenital) or acquired; acute versus chronic duration.
3. Distribution mapping — Document body regions involved; flexural involvement suggests atopic dermatitis; extensor/scalp involvement suggests psoriasis.
4. Primary lesion characterization — Classify as macule, papule, vesicle, pustule, plaque, or nodule using standardized morphology terminology.
5. Secondary change assessment — Note lichenification, scaling, excoriation, or crusting as indicators of chronicity or secondary infection.
6. Family history screening — Atopy, psoriasis, and genetic genodermatoses carry established heritable patterns.
7. Triggering factor inventory — Identify exposures: new detergents, school contacts, pets, recent viral illness (relevant for guttate psoriasis), dietary changes.
8. Previous treatment documentation — Record topical agent history, including corticosteroid class and duration of prior use.
9. Systemic review for associated conditions — Screen for asthma and allergic rhinitis in atopic children; screen for joint symptoms in pediatric psoriasis; screen for metabolic indicators in acanthosis nigricans.
10. Photodocumentation — Standardized photography at initial visit enables objective comparison across follow-up intervals.

Reference Table or Matrix

The home page of this resource provides an orientation to how pediatric dermatology fits within the broader landscape of skin health topics addressed throughout this reference network.

For conditions such as eczema and atopic dermatitis, acne causes and treatment, psoriasis types and management, fungal skin infections, and [contact dermatitis causes and avoidance

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)